biostudies-literatureKwon DTerry Fox Research InstituteCanadian Institutes for Health ResearchCIHR1628-1639https://www.ebi.ac.uk/biostudies/studies/S-EPMC9365342biostudies-literatureUnknown28(8)<h4>Purpose</h4>Mantle cell lymphoma (MCL) is associated with poor survival. The purpose of this study was to assess whether the C-X-C chemokine receptor type 4 (CXCR4) is a useful target for imaging and radioligand therapy of MCL, using a novel pair of radioligands, [68Ga]Ga and [177Lu]Lu-BL02.<h4>Experimental design</h4>We performed a retrospective analysis of 146 patients with MCL to evaluate CXCR4 expression and its correlation with outcomes. Guided by in silico methods, we designed BL02, a new radioligand labelled with 68Ga or 177Lu for PET imaging and therapy, respectively. We performed imaging and biodistribution studies in xenograft models with varying CXCR4 expression. We evaluated [177Lu]Lu-BL02 in MCL models, and evaluated its potential for therapy in Z138 MCL xenografts.<h4>ResClinical cancer research : an official journal of the American Association for Cancer ResearchTargeting Refractory Mantle Cell Lymphoma for Imaging and Therapy Using C-X-C Chemokine Receptor Type 4 Radioligands.PMC9365342FDN-1484651061Chong LRousseau JMerkens HBenard FFraser BKwon DMiyata-Takata TSteidl CZhang ZLau JKuo HTTakata KAoki TVilla DZeisler JZhang CLin KSTan RUribe CFfalseTargeting Refractory Mantle Cell Lymphoma for Imaging and Therapy Using C-X-C Chemokine Receptor Type 4 Radioligands.<h4>Purpose</h4>Mantle cell lymphoma (MCL) is associated with poor survival. The purpose of this study was to assess whether the C-X-C chemokine receptor type 4 (CXCR4) is a useful target for imaging and radioligand therapy of MCL, using a novel pair of radioligands, [68Ga]Ga and [177Lu]Lu-BL02.<h4>Experimental design</h4>We performed a retrospective analysis of 146 patients with MCL to evaluate CXCR4 expression and its correlation with outcomes. Guided by in silico methods, we designed BL02, a new radioligand labelled with 68Ga or 177Lu for PET imaging and therapy, respectively. We performed imaging and biodistribution studies in xenograft models with varying CXCR4 expression. We evaluated [177Lu]Lu-BL02 in MCL models, and evaluated its potential for therapy in Z138 MCL xenografts.<h4>Res2022-01-01T00:00:00Z2022 Apr2026-07-14T21:12:25.144Z2024-11-20T21:02:47.155ZS-EPMC93653423507886010.1158/1078-0432.CCR-21-3284